Sep 2026· Ecotoxicology and Environmental Safety· Vol 324, pp.
120799
· 0 citations· 25 references
Medicine
TL;DR
Results indicate that SchB attenuates MC-LR-induced hepatic toxicity and suppresses excessive AKT/FOXO1 activation, suggesting SchB as a promising hepatoprotective candidate against MC-LR exposure.
Abstract
Microcystin-LR (MC-LR) is a common biological pollutant found in aquatic environments; it induces severe liver injury, inflammation and lipid metabolic disorders. The potential mechanisms underlying MC-LR pathogenesis is still unclear, and effective therapeutic drugs remain to be explored through in-depth research. This study was designed to systematically evaluate and clarify the protective effects and mechanisms of Schisandrin B (SchB) against MC-LR-induced hepatotoxicity. The animal study indicated that SchB alleviated MC-LR-triggered body weight loss, hepatomegaly, liver dysfunction, inflammatory responses and histopathological damage (all p<0.05). Biochemical analysis and qRT-PCR results demonstrated that SchB ameliorated triglyceride and total cholesterol levels by regulating lipogenic and lipolytic gene expression (all p<0.05). Bioinformatics and molecular docking identified IL-6 as a potential binding target of SchB, with IL-6 was induced by MC-LR. Further, GO and KEGG bioinformatic analysis combined with Western blot demonstrated that SchB attenuated MC-LR-induced excessive AKT-FOXO1 cascade activation (all p<0.05), and SC79, a selective AKT activator, partially reversed the hepatoprotective effects of SchB, as evidenced by altered serum ALT/AST levels, hepatic inflammatory cytokines (TNF-α, IL-6), lipid metabolism-related genes (SREBP1c、SCD1、ACC1、PPARα), and antioxidant indicators (SOD and CAT), a finding further supported by in vivo animal studies (all p<0.05). These results indicate that SchB attenuates MC-LR-induced hepatic toxicity and suppresses excessive AKT/FOXO1 activation, suggesting SchB as a promising hepatoprotective candidate against MC-LR exposure.
The results showed histopathological hepatic damage across treatments, with a significantly decreased hepatosomatic index (HSI) in the high-PHS-exposure group, and Interestingly, the triglyceride content showed significant increases in the PHS-treated groups.
Jiao-Jiao Li, Jun Li, Xiao-Fu Pan· Ecotoxicology· 0 citations
Cholestatic liver diseases are characterized by disrupted bile acid homeostasis, oxidative stress, and inflammation, ultimately leading to progressive hepatic injury. Although ursodeoxycholic acid (UDCA) remains the standard pharmacological therapy, its therapeutic efficacy is limited in several cholestatic conditions....
Amany M. Hamed, D. Al-Nouri, N. Mahrous et al.· International Journal of Mol...· 0 citations
Alcoholic liver disease (ALD) is a major global health burden. Cuproptosis, a form of regulated cell death, plays a critical role in multiple liver diseases, yet its role and mechanisms in ALD remain largely unknown. This study explored the preventive and therapeutic roles of mangiferin monosodium salt (MG-Na) against...
Qing-Qing Zhang, Chong-Zheng Pang, Le-Hua Chen et al.· Toxicology and Applied Pharm...· 0 citations
Mycotoxin contamination of food and feed is an increasing global health concern, particularly due to Fusarium toxins such as the regulated deoxynivalenol (DON) and the emerging enniatin B (ENNB). However, the combined mechanisms of action of these toxins remain poorly understood. This study aimed to assess their toxic...
D. Habauzit, Sylvie Huet, Emeline Nicolas et al.· Environment International· 0 citations
Collectively, ZEA promotes hepatic lipid accumulation via stabilization of the EGFR-HSP90 complex and activation of the EGFR-SREBP1c axis, suggesting EGFR as a potential therapeutic target.
Bing-Xin Huangfu, Teng Wang, Jie Li et al.· Food Research International· 0 citations